Mesoblast submits BLA for remestemcel-L to treat aGVHD in children
Category: #health  | By Nikita Chaurasia  | Date: 2019-05-31 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Mesoblast submits BLA for remestemcel-L to treat aGVHD in children

Mesoblast Limited has reportedly filed a rolling submission for Biologics License Application with the U.S Food and Drug Administration for remestemcel-L to treat steroid-refractory acute graft versus host disease in children.

Sources claim that the FDA has approved a rolling review of the BLA which allows individual components to be submitted and evaluated on a regular basis rather than waiting for the completion of all the sections. The rolling process will offer opportunities for consistent communication, and during this process, the company believes it will be able to effectively address any important matters brought up by the FDA. Remestemcel-L has achieved Fast Track designation for aGVHD, under which Mesoblast plans to request a priority review after its BLA filing is completed and accepted by the FDA, cited credible sources.

Dr. Silviu Itescu, Chief Executive of Mesoblast, said that the initiation of the company’s rolling BLA submission to the FDA for U.S approval of its first product is a significant corporate milestone and a historic moment for the company. Moreover, the company is looking forward to making the therapy available to children with this distressing condition at the soonest, Itescu added.

For the uninitiated, over 30,000 allogeneic bone marrow transplants are conducted globally every year, mainly  for patients with blood cancers, with almost 50% developing aGVHD. The six-month mortality rate in severe forms of the condition such as Grades C/D or III/IV, are as high as 90%.

According to sources familiar with the process, in the company’s Phase 3 trial comprising 55 children affected with aGVHD, 89% subjects with Grade C/D disease were treated through remestemcel-L resulting in a six-month survival rate of 69%. Additionally, the overall response at day 28, which was observed in 69% of patients, estimated the highest survival at day 100 and day 180, which accounted for 85% and 79%, respectively. The trial successfully achieved its key endpoint of increased day 28 overall response as opposed to a protocol-defined historic control rate of 45%.

Source Credit
http://investorsmedia.mesoblast.com/static-files/4232b4cb-8942-476b-b002-cda7e3c42cc6

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...

Pure Health invests $500M in Ardent to expand the company footprint

Pure Health invests $500M in Ardent to expand the company footprint

By Nikita Chaurasia

Pure Health, an integrated healthcare solutions platform, publicized its plans to procure a minority equity share in Ardent Health Services, one of the leading US-based healthcare companies, with an investment of $500 million. According to credibl...